Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

@article{Kis2017LiverDirectedTF,
  title={Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma},
  author={Bela Kis and Ghassan El-Haddad and Rahul A. Sheth and Nainesh Parikh and Suvranu Ganguli and Paul B. Shyn and Junsung Choi and Karen T Brown},
  journal={Cancer Control : Journal of the Moffitt Cancer Center},
  year={2017},
  volume={24}
}
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver… 

Tables from this paper

Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
TLDR
This review explores the outcomes of chemoembolization, bland emblization, radioembolizations, and percutaneous ablative therapies for HCC and focuses on prognostic factors related to each of the respective techniques.
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies
TLDR
This review explores recent advances in liver-directed techniques for HCC including bland transarterial embolization, chemoembolized, radioembolizations, and ablative therapies, with a focus on patient selection, procedural technique, periprocedural management, and outcomes.
Ablation of Intrahepatic Cholangiocarcinoma.
TLDR
An overview and update of the medical literature demonstrating ablative therapy as a treatment option for intrahepatic cholangiocarcinoma is provided.
Hepatocellular Carcinoma: Combined Transarterial Chemoembolization and Ablation.
TLDR
The purpose of this article is to provide the trainee with a primer on the use of combined TACE ablation, including a literature review of combined therapy.
Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies.
TLDR
Patient selection and detail outcomes of radioembolization for intrahepatic cholangiocarcinoma are reviewed, together with mention of competing treatments.
Hepatectomy is associated with survival in intrahepatic cholangiocarcinoma
TLDR
Results indicated that LR was associated with a survival benefit for marginal patients with stage I-III ICC, and better survival effects of LR on OS and DSS were consistent across all subgroups.
Factors affecting the response to treatment and survival in hepatocellular carcinoma patients treated with transarterial radioembolisation: a single-centre experience
TLDR
Y-90 microsphere radioembolisation is a safe method and may be helpful in treating patients with unresectable hepatocellular tumours and higher alpha-fetoprotein levels before and after treatment could predict survival rates.
LI-RADS treatment response lexicon: review, refresh and resolve with emerging data
TLDR
An overview of the evolution of the treatment response algorithm, its current applicability and its outlook for the future is provided.
...
...

References

SHOWING 1-10 OF 219 REFERENCES
Liver-directed therapies for patients with primary liver cancer and hepatic metastases
TLDR
In patients with primary liver cancer, underlying liver disease often prohibits surgical intervention, however, survival advantages have been gained with the application of percutaneous alcohol injection and radiofrequency ablation, and RFA has all aided in prolonging survival.
Intrahepatic Cholangiocarcinoma
TLDR
It is concluded that hepatic resection is indicated for intrahepatic cholangiocarcinoma when it is deemed resectable and patients without lymphatic permeation or hilar nodal metastases survived significantly longer.
Multimodality treatment of intrahepatic cholangiocarcinoma: A review
TLDR
Optimizing the use of current and developing novel multimodality treatment for iCCA is essential to improving outcomes.
Work in progress: transcatheter management of primary carcinoma of the liver.
TLDR
Twenty-four patients with hepatocellular carcinoma or cholangiocarcinoma were treated with hepatic artery infusion (HAI) of chemotherapeutic agents (14 patients) or hepatic arteries embolization (HAE) or a combination of the two treatments.
Prognosis of hepatocellular carcinoma: the BCLC staging classification.
TLDR
A new staging system is proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available, based on prognostic factors obtained from studies performed years ago.
Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.
Treatment of intermediate-stage hepatocellular carcinoma
TLDR
Current approaches used to accurately stratify patients with intermediate-stage HCC and subsequently allocate the most-appropriate treatments are reviewed and radioembolization is a promising alternative that deserves further prospective studies.
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses
TLDR
The major findings from meta-analyses comparing different treatment options for hepatocellular carcinoma were reviewed, and the recommendations and uncertainties regarding the treatment of HCC were proposed.
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives
TLDR
This overview will describe the biological rationale for Y90, highlight seminal data, propose research questions and discuss the future role of Y90 in HCC.
Hepatic artery infusion and chemoembolization in the management of liver metastases
TLDR
Intraarterial infusion of chemotherapy, embolization, and chemoembolization for hepatic metastases is based on the dual blood supply of the normal liver and that of the tumors and enhances the delivery of therapeutic agents to the liver.
...
...